Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 22, Pages 9370-9382Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm500670d
Keywords
-
Categories
Funding
- Trinity College IITAC research initiative (HEA PRTLI)
- Enterprise Ireland (EI)
- Science Foundation Ireland (SFI)
- Health Research Board (HRB)
- Trinity College
- Irish Research Council Government of Ireland Postdoctoral Fellowship [GOIPD/2013/188]
- Cycle 5 of the Irish Higher Education Authority's Programme for Research in Third Level Institutions (PRTLI)
Ask authors/readers for more resources
Twelve novel beta-lactams were synthesized and their antiproliferative effects and binding affinity for the predominant isoforms of the estrogen receptor (ER), ER alpha and ER beta, were determined. beta-Lactams 23 and 26 had the strongest binding affinities for ER alpha (IC50 values: 40 and 8 nM, respectively) and ER beta (IC50 values: 19 and 15 nM). beta-Lactam 26 was the most potent in antiproliferative assays using MCF-7 breast cancer cells, and further biochemical analysis showed that it caused accumulation of cells in G(2)/M phase (mitotic blockade) and depolymerization of tubulin in MCF-7 cells. Compound 26 also induced apoptosis and downregulation of the expression of pro-survival proteins Bcl-2 and Mcl-1. Computational modeling predicted binding preferences for the dual ER/tubulin ligand 26. This series is an important addition to the known pool of ER antagonists and beta-lactam 26 is the first reported compound that has dual-targeting properties for both the ER and tubulin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available